Chattem Q4 and FY 2008
This article was originally published in The Rose Sheet
Executive Summary
Product innovation and continued advertising support will keep up the firm's momentum in 2009, according to Chattem's Jan. 29 earnings announcement. Firm booked $105.5 mil. in revenue for its fiscal 2008 fourth quarter, a 4.9% increase from the prior-year period. Strong performances from Gold Bond, Icy Hot, ACT, Aspercreme and Bullfrog were offset by reduced sales of Selsun Blue, Dexatrim and Capzasin and the voluntary recall of Icy Hot Heat Therapy. For the full year, sales totaled $454.9 mil., up 7.4%, and net income was $66.3 mil. Advertising and promotional expenses rose by $5.9 mil. to $118.1 mil. Chattem expects earnings per share in fiscal 2009 to be in the $4.80-$5 range. Firm remains confident that the weak economy and erosion of consumer confidence will not hurt its business (1"The Rose Sheet" Nov. 24, 2008, p. 10)
You may also be interested in...
Chattem Has High Hopes For New ACT, Selsun Launches, Raises Guidance
Chattem, unfazed by the state of the economy and supremely confident in new launches within its ACT, Gold Bond and Selsun brands, is setting its fiscal 2009 expectations at 60 cents to 75 cents per share above its 2008 guidance
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.